MedTrace Logo

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

NCT01910441 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2015-10-28

Study results available
· View outcomes & findings →

Summary

Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.

Conditions

Interventions

DRUG

Vildagliptin

Vildagliptin 50 mg twice daily

DRUG

Glimepiride

Glimepiride 1-6 mg once daily

DRUG

Metformin

Metformin (1000-1500 mg daily)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-09-30
Completion
2014-09-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01910441 on ClinicalTrials.gov